Capricor Therapeutics, Inc. (CAPR)

NASDAQ • Healthcare

$9.4

+$0.12 (+1.3%)

Market closed

Last close at September 4, 2026 at 20:00 UTC

Day Range$9.26 - $9.81

Avg. Volume (3M)10.9M

Market Cap$540.5M

52 Week Range

$2.96$40.37

Next EarningsIn 66 daysNov 9, 2026

Metrics Over Time

Fundamentals & Financials

Revenue (TTM)

Net Income (TTM)

-$129.4M

EPS (TTM)

-$2.45

ROA (TTM)

-35.1%

Current Ratio

7.35

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings

-18.7%Q3 2025-$0.57

0.0%Q4 2025-$0.54

-21.6%Q1 2026-$0.62

-7.3%Q2 2026-$0.59

-18.9%Q3 2026-$0.7

Nov 9

in 66 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

View full earnings history

About Capricor Therapeutics, Inc.

Capricor Therapeutics, Inc. is a small-cap biotechnology company listed on NASDAQ as CAPR that develops cell and exosome-based therapeutics. Its work centers on rare and serious diseases, with a pipeline built around programs aimed at Duchenne muscular dystrophy and other conditions with unmet medical needs.

Name

Capricor Therapeutics, Inc.

CEO

Linda Marbán

Website

www.capricor.com

Industry

Healthcare

Year Founded

1996

Employees

231

Today's Snapshot

AI-generated

CAPR closed 1.3% higher at 9.40, outperforming a weaker sector. Shares changed hands at about a quarter of its usual level. Capricor Therapeutics launched a legal fight over its Duchenne muscular dystrophy therapy ahead of FDA review.

Trading Volume

Below 10d avg (9.0M)

2.4M

vs S&P 500 Today

Outperforming Market

+1.71%

Updated: September 4, 2026 at 20:01 UTC

Technical Indicators

2 Buy3 Neutral3 Sell

CAPR presents mixed signals that skew negative: short-term moving averages and recent momentum are positive, and OBV is strong, indicating demand, yet the price remains below the 50/100/200-day averages and ATR is high, implying elevated risk from large intraday moves. ADX denotes a moderate trend, but MACD is not confirming a clear bullish shift and classic pivots are neutral, leaving the longer-term technical bias unfavourable despite near-term strength. Technical takeaway: Sell — shorter-term strength is offset by weakness under longer-term moving averages and high volatility.

All signals